Aarti Drugs credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
575575612562607
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
566566605553598
0.37×0.37×0.45×0.44×0.51×
0.37×0.37×0.44×0.43×0.50×
1.86×1.86×2.13×1.78×1.98×
1.70×1.83×2.11×1.75×1.96×
7.19×7.19×6.45×7.91×7.67×
27.1%27.1%30.9%30.5%33.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIDRUGS₹375.00

Aarti Drugs Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹3,423 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt606.5562.4612.2574.8574.8
Net Debt597.6553.0604.7566.0566.0
Total Debt/Equity0.510.440.450.370.37
Net Debt/Equity0.500.430.440.370.37
Total Debt/EBITDA1.981.782.131.861.86
Net Debt/EBITDA1.961.752.111.831.70
Interest Coverage (EBIT/Interest)7.677.916.457.197.19
Total Debt/Total Capital %33.7130.4930.9027.0627.06
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.